Please login to the form below

Not currently logged in
Email:
Password:

Emend

This page shows the latest Emend news and features for those working in and with pharma, biotech and healthcare.

CHMP October meeting gives recommendations for Pfizer and MSD

CHMP October meeting gives recommendations for Pfizer and MSD

Merck Sharpe &Dohme's Emend (aprepitant) was further recommended for the prevention of nausea and vomiting in child chemotherapy patients from the age of 6 months to 12 years.

Latest news

  • Merck plans expanded filing for Emend this year Merck plans expanded filing for Emend this year

    Merck &Co's nausea and vomiting therapy Emend is effective in preventing chemotherapy-induced nausea and vomiting (CINV) even when given as a single dose, says a new study. ... Emend has been a solid product for Merck &Co, with sales last year rising 9%

  • Breathing easier

    Allergic rhinitis . Japan. Aprepitant . Emend (Ono Pharmaceutical). Chemotherapy-induced nausea and vomiting  .

  • Breathing life

    Aprepitant. Emend (Ono Pharmaceutical). Chemotherapy induced nausea and vomiting. Japan. Sitagliptin.

  • Cost of living

    For example, anti-nausea drugs in the NK-1 class such as Emend make chemotherapy more manageable for high-need patients, thereby improving the likelihood of success for the primary therapy.

  • Elan and J&JPRD submit NDA for novel Invega reformulation

    Rapamune (sirolimus), which is marketed by Wyeth: and the anti-emetic treatment Emend (aprepitant), which is marketed by Merck &Co.

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics